The President of Colombia, Ivan Duque, said on 25 February 2021 that Colombia will extend its health state of emergency to curb the spread of COVID-19 by three months, Reuters news agency reported on Friday.
Colombia's health state of emergency was due to end on 28 February 2021, but will now continue until at least 31 May 2021, Duque said, adding, "The large majority of countries are upholding states of emergency and we will do the same."
Large public events, including concerts, will continue to be suspended, although a return to schools will go ahead, with students alternating between virtual and physical attendance.
Also, Colombia is in talks to buy additional doses of COVID-19 vaccines produced by China's Sinovac Biotech.
Duque added in his nightly television broadcast: "We have also progressed with Sinovac for the additional acquisition of vaccines in our country, which could be around 10 million more doses."
Colombia has already secured five million extra Sinovac doses and is in talks to secure up to an additional five million, Duque was quoted as saying.
Reportedly, Colombia had earlier announced agreements with a several pharmaceutical companies, including Sinovac, as well as the World Health Organisation-backed COVAX initiative, to secure 61.5 million COVID-19 vaccine doses, enough to inoculate about 32.5 million people.
According to the health ministry of Colombia, the country has so far reported over 2.24 million COVID-19 infections, as well as 59,396 deaths.
So far, Colombia has administered 66,000 vaccine doses to health workers and those aged over 80, as per its national vaccination plan.
Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine
4basebio announces strategic collaboration with Genezen
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
Sanofi's MenQuadfi receives EU approval for infants from six weeks
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
Evaxion presents new preclinical data on cytomegalovirus vaccine EVX-V1
Northwest Biotherapeutics presents on propensity score matching at BNOS 2026
Taiwan biomedical startups hold over 100 business meetings at BIO 2026
SK bioscience to lead Gates Foundation-funded ROTOR project
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
Transgene expands myvac platform into non-small cell lung cancer with TG4070
Replicate Bioscience awarded Gates Foundation grant to advance srRNA vaccine candidates for TB